新闻

RapAdmin

Researchers at China Agricultural University took fecal microbiota from healthy human donors aged 22 to 29 and 70 to 85, and transplanted them into antibiotic-depleted Bama miniature pigs. Seven days after colonization, pigs carrying elderly human microbiota showed shorter ileal villi, lower levels of three tight junction proteins across jejunum, ileum and colon, and roughly two and a half times higher circulating diamine oxidase, a blood marker of leaky gut. Plasma metabolite profiles diverged, with five metabolites separating the groups. Cell culture work confirmed that two of those metabolites moved barrier resistance in opposite directions. Ileal gene expression showed a coordinated shutdown of interferon-stimulated genes in the elderly group. The design is correlative at the mechanism level, the sample is six pigs per group, and the observation window is one week.

The idea that an aged gut microbiome is not just a passenger but a driver of age-related decline has been tested mostly in mice. Mice are cheap and tractable, but their gut is a poor stand-in for ours: different fermentation site, different transit, different diet. This study swapped the model. Pigs eat like us, ferment in the colon like us, and their small intestine scales to body weight roughly the way ours does. That makes the result harder to dismiss as a rodent artifact.

The setup was simple. Eighteen two-month-old male miniature pigs were divided into three groups of six. Two groups were emptied out with a three-day antibiotic cocktail, then given alternate-day gavages of human fecal slurry over eight days, drawn either from five young donors or five elderly donors. A third group received nothing. After a week of colonization the animals were euthanized and their intestines examined.

The transplants took. Microbial richness bounced back to baseline, but the community composition was reshaped and the young and elderly communities stayed distinguishable from each other. Pigs given elderly microbiota carried more Blautia obeum, a species previously linked to worsened colitis in mice and to altered glucose handling in humans. Pigs given young microbiota carried more Phocea massiliensis, a species that declines with age in mice and tracks inversely with frailty scores.

The host responded fast. Villi in the ileum, the segment doing most of the final nutrient absorption, were about a fifth shorter in the elderly group. Duodenum, jejunum and colon architecture were unchanged, which argues for a segment-specific vulnerability rather than generalized damage. Tight junction proteins ZO-1, claudin-1 and occludin dropped by roughly a third to a half depending on segment. Diamine oxidase in blood, which rises when the intestinal lining is compromised, climbed sharply.

The metabolite story was the most mechanistically satisfying part. A dipeptide, Tyr-Phe, fell in elderly recipients and correlated positively with tight junction levels. Prostaglandin E3 rose and correlated negatively. When the team applied each to cultured pig intestinal cells, Tyr-Phe raised barrier resistance and prostaglandin E3 lowered it, which is what the correlations predicted.

The transcriptomics complicate the picture. Seven hub genes, all interferon-stimulated, were downregulated in elderly recipients. The authors read this as a weakened baseline antiviral tone in the epithelium. That reading is plausible but not tested here, and it sits awkwardly with the usual inflammaging narrative of an over-activated aged immune system.

Actionable Insights

What the study does is put a number on how quickly a microbial community can degrade barrier function in a human-like gut.

The magnitudes matter more than the p-values. Ileal villus height fell about 21 percent, with a standardized effect size near 1.4. In plain terms, an effect size of 1.4 means the average elderly-microbiota pig sat well outside the range where most young-microbiota pigs clustered. Tight junction protein reductions ran 32 to 47 percent with effect sizes between roughly 2.1 and 3.0, which is very large by the usual convention that 0.8 counts as large. Blood diamine oxidase rose about 146 percent, effect size near 2.0.

The practical reading is that donor age, not the recipient’s age, drove all of this. The pigs were two months old. Whatever the elderly microbial community carried was sufficient to degrade barrier proteins in a young host within a week. That supports the general case for attending to gut community composition, and it puts specific candidates on the watch list: Blautia obeum as a possible liability marker, Phocea massiliensis as a possible favorable one. Neither is measurable on a consumer stool test with any reliability, and neither is modifiable by any validated intervention at present.

There is no lifespan data, no human endpoint, and no tested intervention. Anyone selling a probiotic on the back of this paper is ahead of the evidence.

Context and Source

相关阅读:

RapAdmin

Researchers at Leiden University gave rapamycin to naturally aged male mice that already had advanced atherosclerosis. After eight weeks, plaque size, collagen and necrotic core were unchanged. The immune environment was substantially remodeled. Plaque macrophage staining fell about 23 percent. Aortic neutrophils and CD8 T cells dropped. Regulatory T cells rose as a share of helper T cells. Germinal center B cells, antibody levels and age-associated B cells fell sharply in plaque-draining lymph nodes. Some senescence markers declined. The costs were a 25 percent rise in blood cholesterol and broad suppression of antibody-producing immunity.

Rapamycin has spent two decades as the most reliable lifespan-extending drug in mice, and a growing number of people take it off-label hoping to slow their own aging. A new study from Leiden University asks a narrower, clinically pointed question: what does the drug do to the immune system of an old animal that already has advanced arterial disease?

The answer is that it reshapes that immune system substantially, but it does not shrink the plaques.

The team used male mice lacking the LDL receptor, a standard model for human-like cholesterol problems. The mice aged on ordinary chow until they were 80 to 90 weeks old, roughly comparable to people in their late fifties to mid-sixties. By then the animals carried arterial plaques built up slowly over a lifetime rather than forced by a high-fat diet. Half then received rapamycin injections three times a week for eight weeks. The others received a placebo solution.

Plaque size did not change. Neither did collagen content or the necrotic core, the dead, debris-filled center that makes human plaques prone to rupture. What changed was the cellular makeup. Rapamycin-treated plaques held about 23 percent less macrophage staining. Macrophages are the immune cells that swallow cholesterol and become foam cells. In the aortic wall, neutrophils dropped by roughly two-thirds and killer CD8 T cells by more than half. Meanwhile, the share of regulatory T cells, which calm inflammation and are thought to help stabilize plaques, rose from about 57 to 71 percent of helper T cells.

The effects were much larger in the lymph nodes that drain the heart and aorta. There, total immune cell counts fell almost six-fold. Germinal centers are the lymph node sites where B cells learn to make high-affinity antibodies, and they all but disappeared. Blood levels of IgM and several IgG subclasses fell by 40 to 60 percent. Age-associated B cells also declined. These cells accumulate with age and are linked to autoimmunity and chronic inflammation.

Gene expression hinted at a partial rollback of immune aging. Senescence scores fell in several aortic immune cell types. Spleen cells expressed less p16 and Btg2, two hallmarks of aging cells. Two other senescence markers, p21 and p53, did not change.

The trade-offs are real. Blood cholesterol rose 25 percent, a side effect already well documented in transplant patients on mTOR inhibitors. The same suppression of germinal centers and antibodies that looks anti-inflammatory inside an artery could weaken responses to vaccines and infections in an older person. The spleen also showed more interferon-gamma-producing helper T cells, and more helper T cells that had lost CD27, a marker of heavily used, late-stage cells.

The authors present the work as a case for “immune rejuvenation” in older cardiovascular patients, possibly combined with statins to offset the cholesterol rise. The study shows a quieter, more regulated immune landscape around established plaques. It does not show that plaques grew less, or that the mice had fewer cardiac events or lived longer. Those are the outcomes that ultimately matter.

Actionable Insights

This is a short mouse study with no clinical endpoints. It supports hypotheses, not prescriptions. With that caveat, four practical points emerge.

First, do not expect rapamycin alone to shrink existing plaque. What improved was plaque inflammation. Macrophage content fell about 23 percent, a moderate-to-large effect (a treated mouse had roughly a 71 percent chance of scoring better than a control).

Second, monitor lipids. Total cholesterol rose 25 percent, from about 258 to 323 mg/dL. That is a large effect (roughly an 83 percent chance a treated mouse ran higher than a control), and it matches human transplant data. Anyone using rapamycin who has cardiovascular concerns should track an ApoB or lipid panel. Pairing with lipid-lowering therapy deserves a conversation with a clinician.

Third, consider vaccine timing. Germinal center B cells in the draining lymph nodes fell about 97 percent, and IgM fell about 61 percent. This used a fairly intense regimen, and low-dose human trials have shown better vaccine responses, so dose and schedule likely matter.

Fourth, the regulatory T cell shift (up about 13 percentage points) is the most plausible benefit mechanism, but it remains unproven in humans.

Context and Source

RapAdmin

Using MRI, standard histology and a high-resolution light microscopy pipeline (FIM-ID), this study measured skeletal muscle at the whole-muscle, fibre and myofibril levels in young and older adults and in young and old mice, including mice with one hindlimb immobilised for 10 days. In both species, age-related shrinkage of fast-twitch (SERCA1-positive, Type II) fibres came mainly from fibres having fewer myofibrils, not from individual myofibrils getting thinner. Disuse in mice worked the same way. Slow (Type I) fibres in humans were spared. The authors conclude that loss of myofibril number is a conserved mechanism of fibre atrophy and a possible therapeutic target.

Every muscle fibre is packed with hundreds to thousands of myofibrils, the protein cables that actually generate force. When a fibre shrinks with age or bed rest, there are two ways it could happen. Each cable could get thinner, or the fibre could carry fewer cables. The field has known for about fifty years that fibres shrink. It has not known which of these two things is going on, mostly because counting myofibrils by electron microscopy is extremely slow work.

A team led by Troy Hornberger at the University of Wisconsin-Madison, working with Christopher Sundberg’s group at Marquette University, now has an answer. They used a light microscopy method they built, called FIM-ID. It images myofibrils with enough contrast for software to trace them automatically. With it they measured muscle at three scales in 34 young and older adults, and in young and old mice. Some of the mice had one hind leg immobilised for ten days.

In people, the top-line result was familiar. Adults aged 65 to 84 had about a third less quadriceps volume on MRI than adults aged 19 to 40. Under the microscope, the fast-twitch Type II fibres were about 23% smaller in older people. Slow Type I fibres were untouched. The new finding came from the smallest scale. Individual myofibrils in the older fast fibres were the same size as in young fibres. What had changed was how many there were, down by roughly a quarter. Missing myofibrils accounted for almost all of the fibre shrinkage.

Mice showed much the same pattern. Old mice had fewer myofibrils per fast fibre. They also had some myofibril thinning, mostly in a muscle rich in a highly glycolytic fibre type (IIb) that humans do not have. Ten days of immobilisation in young mice cut soleus fibre area by about a third. Again, most of that came from losing myofibrils, with only slight thinning of the ones that remained. Old mice lost less muscle when immobilised. The authors think their muscles were already partly deconditioned by low daily activity.

Why does the distinction matter? If ageing muscle thinned every cable evenly, that would point to a general imbalance between protein building and breakdown. Losing whole cables points to something more specific: a failure in myofibril turnover. The muscle may be removing myofibrils whole, failing to build or split new ones, or both. That narrows the target list. It includes the machinery that assembles new myofibrils in response to mechanical load, which this lab has previously shown drives muscle growth.

The caveats are real. The human data are a snapshot comparing different people, not the same people followed over time, so they cannot show the order of events. Only one thigh muscle was biopsied, and about 30 fibres per person were analysed in detail. The myofibril “count” is calculated from areas, not tallied one by one. The study measured structure, not the molecular signals behind it, and it tested no treatment. What it gives is a clean map of where the muscle goes. That map is needed before anyone can design a way to stop the loss.

Actionable Insights

This paper tested no intervention, so everything below is an inference, not a demonstrated benefit.

  1. The loss is large and concentrated. Older adults had about 34% less quadriceps volume. Within each sex, that is a Cohen’s d of about 2, which is very large: the typical older person fell below nearly every young person of the same sex. The damage sat in fast-twitch fibres, which shrank about 23% (d about 0.8, large). Slow fibres were unchanged. Fast fibres supply power, quick reactions and fall recovery.
  2. Train the fibres that are being lost. Walking and light cardio mostly use slow fibres. Heavy or explosive resistance training recruits fast fibres. The case for this comes from the broader exercise literature, not this study. This paper explains why fast fibres are the ones to target.
  3. Treat disuse as structural damage. In young mice, 10 days of immobilisation removed 23% to 35% of mass in several leg muscles. Most of that loss was whole myofibrils, which have to be rebuilt rather than simply refilled. After injury or surgery, keep unloading periods short and start loading as early as your clinician allows.
  4. Old muscle lost less during immobilisation only because it started lower. That is not protection.

Context and Source

  • Open Access Paper: Macroscopic to ultrastructural analyses identify the loss of myofibrils as the primary mediator of ageing- and disuse-induced muscle fibre atrophy
  • Institutions: University of Wisconsin-Madison (Department of Comparative Biosciences; Division of Geriatrics and Gerontology) and Marquette University (Exercise and Rehabilitation Sciences), with an affiliation at Sohag University, Egypt
  • Country: USA
  • Journal: The Journal of Physiology (published online 25 September 2026)
  • Impact evaluation: The journal’s publisher page currently lists a CiteScore of 7.2 and a Journal Impact Factor of 4.6. The impact score of this journal is 4.6 (JIF), evaluated against a typical high-end range of 0-60+ for top general science, therefore this is a Medium impact journal.

相关阅读:

RapAdmin

This narrative review from Shenzhen University argues that senescent cells are central to skin aging. It covers four skin cell types (fibroblasts, macrophages, keratinocytes and epidermal stem cells), how damage from UV-driven oxidative stress and DNA damage spreads between cells through the SASP and extracellular vesicles, and how histone modifications keep aged skin macrophages in an inflammatory state. It then surveys interventions: senolytics (navitoclax, dasatinib plus quercetin, fisetin), senomorphics (rutin, rapamycin, metformin), stem cell and secretome therapies, nanocarrier delivery, and machine-learning senolytic discovery. It contains no new data. Most of the evidence it summarizes comes from cell culture, rodents and human skin grafted onto mice. The human trials it cites are small, short, and mostly split-face cosmetic studies.

Skin shows age sooner than any other organ, and the authors argue it shows it for a specific reason: old, damaged cells that refuse to die.

These are senescent cells. They stop dividing but stay metabolically active, and they release a cocktail of inflammatory signals, enzymes and small vesicles known as the senescence-associated secretory phenotype, or SASP. In skin, the review says, the main senescent populations are fibroblasts in the dermis, keratinocytes in the outer layer, immune macrophages, and the stem cells that normally replenish the epidermis and hair follicles.

Each population fails differently. Senescent fibroblasts make less collagen and more of the matrix metalloproteinases (MMPs) that break collagen down. The authors describe a feedback loop: fragmented collagen reduces the mechanical tension fibroblasts feel, which raises their internal oxidative stress, which drives further MMP production. Senescent keratinocytes renew the epidermis more slowly, thinning the barrier and letting moisture out and bacteria such as Staphylococcus aureus in. Aged macrophages get stuck in an inflammatory mode and fail to shift into the repair mode that heals wounds.

The review’s more unusual contribution is its attention to how the damage spreads. Senescent cells release more extracellular vesicles than young cells. UV-damaged cells may export fragments of their own DNA in these vesicles, and neighboring cells detect the foreign DNA through the cGAS-STING immune sensing pathway and become senescent in turn. Vesicles also carry microRNAs, such as miR-30a, that suppress renewal in young keratinocytes. The authors also compile evidence that epigenetic regulators, including the enzymes JMJD3, MOF and SETDB2, lock macrophages into a chronic inflammatory state. Much of that evidence, however, comes from diabetic wounds rather than aged skin.

On treatments, the authors cover the familiar longevity pharmacopeia. Navitoclax clears senescent dermal fibroblasts in mouse and human-skin-graft models but causes low platelet and neutrophil counts when taken systemically. Dasatinib plus quercetin, and fisetin alone, reduce senescent fibroblast counts in similar models. Rutin, a quercetin glycoside, acts more as a SASP dampener than a cell killer. Topical rapamycin gets a mention for one small human trial that found fewer p16-positive cells and more collagen VII. Metformin is included for AMPK activation, mostly on the strength of rodent and worm data.

Stem cell therapy receives equal emphasis. The authors conclude that cell-free products, meaning conditioned media and vesicles from mesenchymal stem cells, are more practical than transplanted cells, which survive poorly after injection. Seven clinical studies are tabulated, and nearly all delivered the product by microneedling.

The review ends by pointing to machine-learning screens that have identified new senolytics, including ginkgetin, periplocin and oleandrin, from compound libraries.

The big idea is coherent: skin aging is a senescence problem that can be spread from cell to cell, and so it should be treatable by removing or silencing senescent cells locally. The weakness is that this remains a hypothesis supported mainly by mechanistic and animal work. The human data are sparse, small and unblinded or confounded more often than not.

Actionable Insights

The most reliable intervention remains the least exotic one. The review repeats a common estimate that UV exposure causes about 80% of visible skin aging. That figure is widely cited but loosely sourced, and the true share is hard to measure. Daily broad-spectrum sun protection is still the highest-return step.

Among topicals discussed, two have small human trials:

  • Rutin cream: In a 40-person, 4-week double-blind study, crow’s feet length fell by about 24% and crow’s feet area by about 27% in the rutin group. These are improvements from each person’s own baseline. The paper did not report a standardized effect size, and 4 weeks is too short to judge durability.
  • Topical rapamycin: In a hand-to-hand comparison, rapamycin cream lowered the senescence marker p16 and raised collagen VII.

Stem cell conditioned media trials all used microneedling, which stimulates collagen on its own. The one trial that compared delivery methods found no difference between groups. Any added benefit from the stem cell product itself remains unproven.

Oral senolytics (fisetin, dasatinib plus quercetin) have no controlled human skin-aging outcome data in this review.

Context and Source

  • Full title: Skin Aging: From Molecular Mechanisms to Therapeutic and Technological Innovations
  • Institution: Medical School, Shenzhen University; Laboratory of Regenerative Medicine, The 2nd Affiliated Hospital of Shenzhen University
  • Country: China
  • Journal: Journal of Cellular and Molecular Medicine
  • Impact evaluation: The impact score of this journal is 4.7, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal.

相关阅读:

RapAdmin

A large, long-running Harvard-led mouse study gave middle-aged mice a high dose of the NAD+ precursor NMN in their drinking water for the rest of their lives. Both sexes accumulated frailty more slowly. Only females lived longer: median lifespan rose by 8.5%. Males got leaner and more active but did not live longer, and their tissues showed more inflammation. The authors also report that NMN caused a more than tenfold rise in a gut bacterium, Anaerotruncus colihominis, which can itself take up NMN, and they argue it helps explain the health benefits. This is a revised, not-yet-peer-reviewed preprint of work first posted in 2024. The female control mice were short-lived, so the lifespan result may reflect a correction of poor baseline health rather than slower aging.

For a decade, NMN has been sold as an anti-aging molecule on the strength of mouse and cell studies that never answered the one question that matters most: does it make a mammal live longer? This study, led by Alice Kane and David Sinclair, is the first serious attempt to answer it, and the answer is a qualified “sometimes.”

The team started C57BL/6 mice on NMN at 13 months of age, roughly the human equivalent of the early 40s. The dose was about 550 mg per kilogram per day, which scales to roughly 3 grams a day for a 70 kg adult, two to three times what human trials usually use. Several hundred mice were followed until natural death, with subsets pulled for health testing and tissue analysis.

The clearest finding is on frailty. Using a 31-item checklist of age-related decline (fur loss, hunched posture, hearing and vision loss, breathing changes), treated mice of both sexes scored better at 18.5 and 21 months. The gain amounts to roughly two and a half months of delayed frailty accumulation.

Lifespan is where the sexes split. Treated females lived about 8.5% longer at the median and 7.9% longer at the 90th percentile. Males showed early separation of survival curves that faded to nothing. Autopsies found no change in tumor burden, which addresses a long-running worry that NAD+ boosters might feed cancer. They did find slightly more kidney inflammation in treated mice.

Males, meanwhile, got the metabolic benefits. They gained less fat in late middle age, burned relatively more fat, and ran around more at night. Yet their liver, muscle and fat tissue showed a gene expression pattern that looked older, not younger: more inflammatory and interferon signaling, less mitochondrial activity. Levels of CD38 and several PARP enzymes, which consume NAD+, went up in males but not females. The authors propose that males burn through the extra NAD+ on DNA repair and inflammation, while females route it into mitochondria. That is a plausible story, but it remains a hypothesis.

The gut microbiome adds a new layer. Isotope tracing suggests that much oral NMN is broken down and reprocessed by gut bacteria before the body uses it. A. colihominis, a butyrate producer previously linked to lower neuroinflammation and enriched in human centenarians, jumped more than tenfold with treatment, and the bacterium took up labelled NMN in culture. The authors float an A. colihominis probiotic as a partner to NAD+ precursors.

The big caveat is the controls. The untreated females died at a median of roughly 26 months, around 790 days. A widely used benchmark holds that healthy lab mice should reach about 900 days before a lifespan gain can be credited to slower aging. Even the NMN-treated females fell short of that line. The more cautious reading is that NMN helped unhealthy female mice catch up toward a normal lifespan. That still matters, since many humans age in less-than-ideal conditions, but it is not the same thing as slowing aging.

Actionable Insights

  • NMN is not a proven lifespan drug. In this study it extended life only in female mice whose untreated lifespan was below normal, and not in males whose controls lived about as long as healthy mice should. The earlier NIH test of a closely related molecule, nicotinamide riboside, found no lifespan benefit in either sex.
  • The most consistent benefit was slower frailty. Treated mice of both sexes carried roughly 1 to 1.7 fewer age-related deficits out of 31. The average treated mouse was less frail than about 74% (males) to 82% (females) of untreated mice. That is a moderate-to-large effect in mice, but it did not show up in grip strength, nest building, or DNA methylation clocks.
  • In males, fat mass at 24 months was about 30% lower in relative terms (roughly 14.5% vs 21% body fat), based on only 7 mice per group.
  • The mouse dose equates to about 3 g per day in humans, well above typical supplement doses. At that dose, treated mice had slightly more kidney inflammation. [Confidence: Medium]
  • Sex may matter. Men and women could respond differently, and no human data yet tests this.
  • Your gut bacteria may help determine how much NMN you actually use.

Context and Source

  • Open Access Paper (Preprint): Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner
  • Institutions: Blavatnik Institute, Harvard Medical School (lead) and the Institute for Systems Biology, Seattle, with contributors from the University of Pennsylvania, Brown University, the University of Rhode Island, NIA/NIH, UNSW Sydney, UT Health San Antonio, ETH Zurich and others
  • Country: United States (lead), with Australian, Swiss and Austrian collaborators
  • Journal: None (preprint server)

RapAdmin

Researchers at the Max Planck Institute for Biology of Ageing disabled cGAS, the cell’s sensor for DNA that has leaked out of the nucleus or mitochondria, in the turquoise killifish, a short-lived vertebrate. The fish looked younger at the tissue level. Their kidneys had about half as many senescent cells, more cells were still dividing, and gene expression profiles looked less aged. Cultured cells resisted radiation-induced senescence. Removing cGAS from birth for the whole life did not extend lifespan, and it came with a cost: more baseline DNA damage. The study also found that pathway activity in the kidney rises about sixfold in old age. That pattern suggests cGAS-STING mainly causes harm late in life, which fits the positive whole-animal data so far: partial STING inhibition started late in life improved brain health in mice. The takeaway is that when and how much you block this pathway probably matters more than whether you block it.

The cGAS-STING pathway has become a leading target in aging biology. When DNA leaks into the interior of a cell, whether from a damaged nucleus or a stressed mitochondrion, the enzyme cGAS detects it and produces the messenger molecule cGAMP. cGAMP activates STING, which triggers an interferon alarm. This defense is essential against viruses. Over decades, though, chronic activation drives inflammaging, the low-grade inflammation linked to neurodegeneration, heart disease and frailty. It also powers the inflammatory secretions of senescent cells.

Adam Antebi’s group in Cologne asked the most direct question possible: what happens if cGAS is removed completely, from conception, in a vertebrate that ages within months? The African turquoise killifish lives about 4 to 8 months and shows many features of vertebrate aging along the way, which makes it well suited for this kind of test.

The biology responded clearly. In fish cells without cGAS, radiation-induced senescence fell by more than half, and the cells kept dividing when normal cells stalled. In live fish, the kidney’s response to radiation damage was muted. By old age, knockout kidneys had about half the senescence staining of normal kidneys, more dividing cells, and gene activity that looked less aged. Programs for DNA replication and repair were less shut down, and the complement and clotting signals typical of inflammaging were less pronounced. The pathway is clearly an active driver of cellular aging signatures in this animal.

Lifespan, however, did not change. Knockout and normal fish died on essentially the same timetable. The key question is why, and the paper’s own data point to an answer.

First, pathway activity is time-dependent. In normal fish, kidney cGAMP levels rose roughly sixfold between youth and old age. For most of the animal’s life the alarm is quiet, so a lifelong knockout pays costs during years when there is little to gain.

Second, total removal has side effects. Killifish cGAS turns out to protect DNA, much as it does in naked mole rats. Knockout cells carried almost four times more baseline DNA damage. The fish also partly compensated by increasing expression of STING and other downstream immune genes, which is a typical response when a component is missing from development onward.

Third, senescence is not purely harmful. It supports wound repair and tumor suppression, so eliminating the signal entirely removes helpful effects along with harmful ones.

Together, these findings fit the more encouraging evidence from mice. In 2023, partial STING inhibition started in old animals reduced brain inflammation and slowed cognitive decline. That approach differs in every important respect: it is late-life rather than lifelong, partial rather than total, and it targets STING rather than cGAS. The killifish result tests the bluntest possible version of the intervention and shows that it is not the right one. It leaves the more refined strategy open, and arguably strengthens the case for it.

Actionable Insights

This paper supports a clear strategic principle: in this pathway, timing and dose probably matter more than total suppression.

First, the target becomes more active with age. In normal fish, kidney cGAMP rose about sixfold from youth to old age. Blocking the pathway early in life brings mostly costs, while late-life intervention aims at the period when the pathway is most active.

Second, total loss has a measurable cost. Cells without cGAS showed about 3.8 times more baseline DNA damage (38 percent vs 10 percent of cells with damage foci). Partial inhibition that keeps some cGAS activity could avoid most of this.

Third, the benefits at the tissue level are real. Kidney senescence fell by about 50 percent and proliferation markers rose by 38 percent or more. A carefully timed intervention would aim to keep these gains without the costs.

Practically, the best evidence still comes from late-life, partial STING inhibition in mice, which improved brain health but was not tested for lifespan. For now, avoid products marketed as broad cGAS or STING blockers for lifelong use. Aspirin, for example, blocks cGAS in cell studies, but there is no longevity evidence for that mechanism. Instead, watch for clinical STING inhibitors being tested in specific late-life inflammatory or neurodegenerative conditions.

Context and Source

  • Open Access Paper: Loss of killifish cGAS attenuates age-related signatures but does not affect organismal life span
  • Institution: Max Planck Institute for Biology of Ageing and CECAD, University of Cologne
  • Country: Germany (with collaborators in the USA and France)
  • Journal: EMBO Reports (published online 9 September 2026)
  • Impact evaluation: EMBO Press reports that the 2025 JIF for EMBO Reports was erroneous and gives a corrected official figure of 6.4. The impact score of this journal is 6.4, evaluated against a typical high-end range of 0 to 60+ for top general science (Nature, Science and Cell sit roughly between 40 and 65), therefore this is a Medium impact journal.

相关阅读:

RapAdmin

A meta-analysis of 69 randomised trials (2,387 adults) mapped how session length relates to fitness gains for high-intensity interval training (HIIT) and moderate-intensity continuous training (MICT). HIIT improved VO2max more than MICT, and its benefit curve flattened quickly. About 11 minutes per session, including recovery intervals, delivered 80% of HIIT’s maximal fitness gain. That is roughly 5 minutes of actual hard work. MICT needed about 52 minutes for a similar gain, and its curve never plateaued. For blood pressure, insulin, lipids and body fat, the two approaches produced statistically indistinguishable results. The curves looked similar in healthy people and in people with cardiometabolic risk factors.

For decades, exercise advice has been framed in minutes: 150 a week, 30 a day, more if you can. This analysis asks a sharper question. How many minutes does each session actually need to be, and does the answer depend on how hard you work?

Researchers from Tübingen, Liverpool and Nijmegen pooled 69 randomised trials that pitted interval training against steady moderate exercise. They then used dose-response modelling to trace how fitness gains change as sessions get longer. Fitness was measured as VO2max, the maximum rate at which the body can use oxygen. VO2max is one of the strongest single predictors of mortality in epidemiology.

Both styles of training worked. Interval training raised VO2max by about 4.4 mL/kg/min on average and steady training by about 2.6. The more interesting finding is the shape of the curves. Interval training showed steep early returns followed by a plateau. Half of its maximal benefit came from sessions under 6 minutes, 80% from about 11 minutes, and there was little extra gain beyond roughly 23 minutes. These times include the rest periods between efforts. Counting only the hard efforts, 80% of the benefit arrived with about 5 minutes of work per session, or about 15 minutes of work per week.

Moderate continuous exercise behaved differently. Its benefits rose in a straight line: every extra minute bought a bit more fitness, up to the longest sessions studied (about an hour). It needed roughly 52 minutes per session to match what intervals achieved in 11, which is the 4.6-fold time saving the authors emphasise. Because the MICT line never flattened, nobody yet knows where its ceiling sits.

The time advantage did not extend to metabolic health. Blood pressure, fasting insulin, triglycerides, BMI and body fat improved modestly with both approaches, and the two did not differ. A higher VO2max did not come with better blood markers. The authors suggest that VO2max depends mainly on the heart’s pumping capacity, which responds strongly to intense efforts. Metabolic markers, by contrast, respond to total energy expenditure and fuel depletion, which either approach can deliver.

The dose-response pattern was also similar in healthy volunteers and in people with overweight, prediabetes, metabolic syndrome or high-normal blood pressure. Baseline fitness and age did not change the results either. That matters because short interval protocols are often assumed to suit only fit, young people.

The caveats are substantial. No trial randomised people to different session lengths. The curves come from comparing different studies that happened to use different durations, so length is tangled up with intensity, interval structure and population. Most participants were sedentary or unfit, most trials lasted about 10 weeks, and none measured hard outcomes like heart attacks or death. The “11 minutes” figure has a 95% confidence interval stretching to 40 minutes.

What the paper shows is that for a time-limited person, intensity buys fitness more efficiently than duration, and the returns from longer interval sessions shrink quickly. It does not show that 11 minutes of intervals is all anyone needs for overall health.

Actionable Insights

  • Short interval sessions work. If you’re doing intervals, gains in aerobic fitness largely level off around 20 to 25 minutes of work plus recovery. About 10 minutes, with roughly half of it at hard effort, captures most of the benefit for an unfit or moderately fit adult.
  • Moderate steady cardio needs time. Plan on 45 to 60 minutes per session to approach similar fitness gains. Longer probably still helps.
  • Expect a real but moderate difference. Across trials, HIIT raised VO2max by about 1.2 mL/kg/min more than MICT, roughly a third of a MET. In large observational studies, each 1 MET of fitness is associated with about 13% lower all-cause mortality. That puts HIIT’s extra edge in the range of a 4% lower mortality risk, and the full HIIT gain (about 1.25 METs) around 15%. These are correlations, not proven effects. In statistical terms, the between-group difference is small (d = 0.38): a randomly chosen HIIT participant beats a randomly chosen MICT participant only about 61% of the time.
  • For blood pressure, insulin and lipids, pick the mode you’ll stick with. Both lowered diastolic pressure by about 3 mmHg, and neither beat the other.
  • Mixing both across the week is a reasonable, evidence-compatible approach.

Context and Source

  • Open Access Paper: Optimising Exercise Prescription: A Meta-Analysis Examining the Dose Response of Exercise Duration on Cardiorespiratory Fitness Following HIIT and MICT
  • Journal: Sports Medicine (Springer), published online 12 September 2026.
  • Institutions: University Hospital of Tübingen and Eberhard Karls University of Tübingen (Germany); Liverpool John Moores University and Liverpool Centre for Cardiovascular Science (UK); Radboud Institute for Health Sciences (Netherlands)
  • Countries: Germany, United Kingdom, Netherlands
  • Impact evaluation: The impact score of this journal is 11.0 (2025 Journal Impact Factor; 5-year JIF 13.7), evaluated against a typical high-end range of 0-16 for the sport sciences category (where the British Journal of Sports Medicine leads at about 15.5 to 16) and 0-60+ for top general science, therefore this is a High impact journal.

RapAdmin

Extracellular vesicles function as critical intercellular communication networks within the bone marrow, but chronological aging fundamentally corrupts this system. Senescent cells weaponize these vesicles by altering their cargo to include inflammatory microRNAs and diminished antioxidant defenses, which suppresses healthy stem cell proliferation and drives age-related immune dysfunction. Conversely, vesicles derived from youthful or pluripotent stem cells retain the capacity to reprogram senescent cells and restore metabolic homeostasis, highlighting a novel mechanism for systemic rejuvenation interventions.

The biological aging of the hematopoietic system has historically been attributed to intrinsic cellular failures like telomere attrition and epigenetic drift. Recent data strongly suggests a non-cell-autonomous driver of tissue decline [Confidence: High]. Extracellular vesicles function as a dynamic communication grid within the bone marrow niche, transferring proteins, lipids, and nucleic acids between stromal cells and hematopoietic stem and progenitor cells. During youth, this vesicle exchange maintains homeostasis by delivering regenerative signals and structural support proteins like tropomyosin-1.

As chronological aging progresses, the accumulation of senescent cells severely corrupts this signaling network. Genotoxic stress and systemic inflammation activate specific transcriptional pathways that accelerate vesicle biogenesis and shedding. These aged vesicles are heavily modified. Senescent stromal and immune cells pack them with senescence-associated secretory phenotype factors, mitochondrial fragments, and specific microRNAs such as miR-183-5p, miR-34a, and miR-21. When healthy stem cells internalize these toxic packages, the delivered cargo actively suppresses proliferation, inhibits normal osteogenesis, and forces a secondary senescence state. This process fundamentally remodels the microenvironment to favor myeloid-biased hematopoiesis and establishes a supportive niche for mutated, malignant clones.

Reversing this pathological communication network offers a distinct therapeutic opportunity. Experimental models demonstrate that administering extracellular vesicles derived from young plasma or youthful stem cells successfully attenuates oxidative stress and partially rejuvenates aged stem cell populations. Youthful vesicles carry protective payloads, including peroxiredoxins and proliferating cell nuclear antigen, which restore telomere replication capacity and mitochondrial dynamics in aged recipients. While systemic administration in preclinical models rapidly reduces inflammatory cytokines and restores marrow homeostasis, the precise molecular targeting mechanics remain incompletely mapped. Addressing how specific vesicle surface signatures interact with distinct hematopoietic subsets will dictate the viability of engineered vesicle therapies for age-related functional decline.

Actionable Insights

Systemic vesicle profiles directly mirror biological age and systemic inflammatory burden. Modulating this network offers practical vectors for longevity interventions [Confidence: Medium].

  • Cellular senescence drives a massive output of inflammatory vesicles. Senescent endothelial cells demonstrate an approximate 3-fold (200%) absolute increase in small vesicle shedding compared to healthy controls. Interventions that reduce total senescent cell burden likely reduce this circulating toxic payload.

  • Telomere attrition correlates with a systemic collapse of healthy vesicle populations. Preclinical models of critical telomere shortening show a 36% absolute reduction in circulating plasma vesicle abundance.

  • Age-related inflammation drastically alters specific vesicular proteins. Grancalcin expression increases by 10 to 15-fold (1000% to 1500%) in aged innate immune cells, driving marrow adipogenesis and skeletal aging.

  • Only 20% to 30% of internalized vesicles successfully release their cargo into the recipient cytoplasm. This highlights that delivery efficiency is naturally low, requiring highly concentrated interventions if exogenous youthful vesicles are utilized therapeutically.

Context/Source

  • Paper Title: The Role of EVs in the Aging Hematopoietic System
  • Institutions: University of Glasgow, UK; University of Veterinary Medicine Vienna, Austria; Mayo Clinic, USA
  • Journal: Aging Cell
  • Impact Evaluation: The impact score of this journal is 7.8, evaluated against a typical high-end range of 0–60+ for top general science, therefore this is a Medium impact journal.

RapAdmin

Researchers developed a machine learning model to calculate biological age by analyzing 140 body composition features from standard noncontrast thoracoabdominal computed tomography scans. The resulting metric, termed the “age gap”, successfully identifies accelerated aging and predicts the onset of major chronic diseases across a longitudinal cohort, providing a highly interpretable, macroscopic biomarker for both clinical risk assessment and longevity interventions.

The longevity field has spent the last decade chasing cellular and molecular clocks, primarily focusing on epigenetic methylation patterns. While scientifically profound, these molecular clocks often lack anatomical interpretability and fail to tell clinicians exactly which organ system is driving a patient’s accelerated aging. This study pivots the focus from the microscopic to the macroscopic by utilizing opportunistic computed tomography imaging to quantify systemic aging through gross anatomical structural changes.

Using a large longitudinal health-screening cohort of 7,837 community-dwelling adults in Japan, researchers deployed an automated deep-learning pipeline to extract 211 quantitative body composition features from 71 anatomical structures. These features included organ volumes, tissue attenuation properties, and localized calcification metrics spanning the cardiovascular, pulmonary, abdominal, and musculoskeletal systems. After statistical filtering to reduce multicollinearity, 140 standardized features were retained to train an ElasticNet regression model against chronological age in a strictly healthy sub-population.

By defining the reference trajectory of normal aging in healthy individuals, the researchers established an “age gap” metric, calculated as the age-adjusted residual difference between a subject’s computed tomography-predicted biological age and their true chronological age. A positive age gap indicates accelerated biological aging.

The predictive validity of this age gap was then tested on independent longitudinal datasets. The data shows that the age gap reliably captures disease-specific heterogeneity. Systemic diseases like hypertension and metabolic disorders were strongly linked to multi-organ alterations, specifically visceral adiposity and reduced pancreatic tissue attenuation. Conversely, localized diseases mapped to organ-specific structural decay, such as lower vertebral attenuation in osteoporosis and elevated Agatston scores for cardiovascular conditions.

The operational advantage of this approach is its scalability and reliance on existing medical data. Noncontrast thoracoabdominal scans are routinely performed worldwide. Approximately 93 million CT examinations are performed annually in the United States across roughly 62 million patients.

By running automated segmentation models like TotalSegmentator in the background of routine radiological workflows, healthcare systems could generate opportunistic biological age reports without requiring novel blood draws or expensive molecular assays. This shifts biological age assessment from a niche biohacking commodity into the realm of standard preventative radiology, allowing for targeted lifestyle modifications years before symptomatic chronic disease onset.

Actionable Insights

This study identifies specific anatomical variables that drive the biological aging clock, offering practical targets for longevity interventions. The data points heavily to tissue quality rather than just tissue volume. Specifically, lower tissue attenuation in skeletal muscle and the pancreas indicates lipid infiltration, a major driver of metabolic aging.

To improve this biological age metric, individuals must prioritize the reduction of visceral and ectopic fat. Strategies include strict glycemic control to prevent pancreatic lipid deposition and resistance training to preserve muscle density (preventing myosteatosis).

The magnitude of this intervention is substantial. The study reveals that individuals in the lowest quartile of biological age (the “youthful” group) experienced a 24 percent relative risk reduction for future age-related diseases over a 10-year period compared to the normal reference group (Hazard Ratio: 0.76). Conversely, every 1 standard deviation increase in the biological age gap increased the overall odds of possessing a chronic disease by 35 percent (Odds Ratio: 1.35) and increased the risk of developing a new chronic disease by 24 percent (Hazard Ratio: 1.24). Atrial fibrillation and ischemic heart disease showed the highest sensitivity to this age gap, with hazard ratios of 1.53 and 1.97 per standard deviation increase, respectively.

You Can Try it out Today - The Tools Are Available Online

You can unlock this macroscopic biological aging data using tools already at your disposal. If you have an existing computed tomography or magnetic resonance imaging scan in a standard NIFTI or DICOM zip format, you can bypass standard blood-based epigenetic clocks and calculate your anatomical biological age for free using a two-step open-source workflow.

First, process your scan through TotalSegmentator, an automated deep learning tool that maps out anatomical structures. TotalSegmentator utilizes advanced neural networks to evaluate three-dimensional data, automatically detecting and outlining dozens of distinct internal structures across the body, including major organs, bones, muscles, blood vessels, and various tissue types. The output delivers detailed segmentation masks that precisely isolate the physical boundaries of these regions, alongside quantitative statistics for each localized structure, such as exact volume and tissue intensity. This comprehensive physical profile is frequently utilized by clinicians and researchers for organ volumetry, body composition profiling, surgical planning, and opportunistic disease characterization.

Second, extract the 140 required body composition features generated by TotalSegmentator and feed them into the CT_BIOAGE machine learning model. The researchers behind this model have made their trained algorithm and source code publicly available for this exact purpose. The model translates your structural tissue data into a final biological age gap. A positive age gap identifies accelerated systemic aging driven by macroscopic factors like visceral adiposity, vascular calcification, and ectopic lipid deposition. This two-step process provides organ-specific, actionable data to target your longevity interventions directly at the tissues driving your biological clock.

Context/Source

  • Open Access Paper: CT-based biological age as a biomarker of aging and age-related disease assessment
  • Institution: Southeast University, The University of Tokyo, Chiba University
  • Country: China, Japan
  • Journal Name: npj Aging
  • Impact Evaluation: The impact score of this journal is approximately 4.9, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

RapAdmin

Researchers have demonstrated that failing energy production in aging heart tissue triggers a detrimental signaling loop that halts the clearance of damaged mitochondria. By intravenously transplanting healthy mitochondria derived from mesenchymal stem cells, the research team successfully restored cellular energy levels, deactivated the harmful signaling pathway, and improved overall cardiac pumping capacity in animal models.

Cardiac aging is characterized by a gradual failure of cellular energy systems and an accumulation of cellular damage. A central driver of this decline is the failure of mitophagy, the cellular recycling system responsible for breaking down defective mitochondria. When this process stalls, damaged mitochondria accumulate, spilling reactive oxygen species and accelerating tissue decay.

A newly identified mechanism explains this recycling failure. In senescent cardiomyocytes, low levels of adenosine triphosphate (ATP) trigger the abnormal accumulation of a protein called hypoxia-inducible factor 3 alpha (HIF-3a). While traditionally viewed as a genetic repressor, HIF-3a acts as an active driver in aging hearts, directly binding to and overexpressing the BNIP3 gene. BNIP3 is a receptor that initiates mitophagy by tagging mitochondria for disposal. However, when BNIP3 is persistently overexpressed, the initiation of mitophagy outpaces the cell’s degradation capacity. The recycling system becomes physically congested with unprocessed mitophagosomes.

To resolve this energy crisis and clear the congestion, researchers turned to mitochondrial transplantation. They isolated healthy mitochondria from bone marrow mesenchymal stem cells and injected them intravenously into mice suffering from accelerated cardiac aging. The exogenous mitochondria integrated into the cardiac tissue, providing an immediate boost to cellular ATP production.

This restoration of energy homeostasis created a profound downstream effect. The renewed ATP supply caused HIF-3a levels to drop, which subsequently normalized BNIP3 expression. With BNIP3 signaling quieted, the mitophagy traffic jam cleared. Cells resumed normal degradation of damaged components, and the structural and functional hallmarks of cardiac aging were reversed.

The findings shift the paradigm of cardiac aging from a model of simple wear and tear to one of reversible energy-sensing dysfunction. The data strongly suggests that metabolic collapse is a primary upstream driver of structural tissue decay, and that restoring bioenergetics can reset the biological age of the myocardium.

Actionable Insights
For individuals focused on health optimization, systemic mitochondrial transplantation is not yet a clinically available or safe intervention. However, the core mechanism provides a clear biological target. Preserving intracellular ATP levels is critical to prevent the pathological activation of the HIF-3a to BNIP3 axis.

Interventions that support continuous mitochondrial ATP generation such as endurance exercise, NAD+ precursor supplementation, or coenzyme Q10 optimization theoretically share the same downstream target as the experimental transplant. By keeping ATP levels high, the heart avoids the metabolic panic state that triggers HIF-3a accumulation.

The purported benefits demonstrated in the paper are substantial. The authors report that restoring energy homeostasis increased the left ventricular ejection fraction from a pathological mean of roughly 42 percent to a recovered mean of 58 percent. This represents an absolute improvement of 16 percentage points and a relative pumping capacity increase of 38 percent. This magnitude of functional recovery highlights that cellular senescence in the heart remains highly plastic and responsive to metabolic interventions.

Context/Source

相关阅读: